< News, Press, & Events

Press Release

Genomenon, Inc. Named TiE20 Award Winner at TiECon Detroit 2018

Genomenon, Inc. Named TiE20 Award Winner atTiECon Detroit 2018

ANN ARBOR, MICHIGAN, Sept 24, 2018 — Genomenon, Inc. has been selected as a 2018 TiE20 Winner for the prestigious TiE20 Awards Program. The company has been recognized for its work in Next Generation Sequencing (NGS) interpretation with theMastermind Genomic Search Engine. Mastermind assists doctors and researchers in connecting patient DNA with the most relevant medical research. The competition is a part of TiECon Detroit 2018, Michigan’s largest conference for entrepreneurs.

“It’s an honor to be selected among this elite list of entrepreneurs and companies by TiE20for our leadership in applying artificial intelligence (AI) to the field of genomic interpretation,” said Mike Klein, CEO, Genomenon, Inc.

TiE20 has become a global brand that attracts thousands of companies worldwide. Selected from more than 500 nominated companies, the winners represent the most enterprising startup companies in five focus segments: Sensors/Electronics/IOT, Food/Health/Fitness, Fintech, Blockchain/AI/ML/DL and Manufacturing/In Vehicle Technologies/Mobility. TiE20 winners will present their companies to the conference attendees. They will get special invitations to premium networking sessions at TiECon and will also be part of ongoing recognition from TiE Detroit throughout the year. More importantly, they will get access toTiE’s powerful global entrepreneurial ecosystem.

"TiE20 awards is where aspirations of today become an entrepreneurial reality of tomorrow. We are confident this is a first step towards identifying and to spotlight the next generation business creators in our region," said Tel K. Ganesan, President, TiE Detroit Chapter.

The TiE20 winners will be honored with awards of excellence at TiECon Detroit 2018 on Saturday, October 06, 2018, at 6:00 p.m at the Suburban Collection Showplace, 46100Grand River Ave, Novi, Michigan.


Genomenon is a genomics intelligence company dedicated to improving the quality of life of genetic disease and cancer patients by making genomic information actionable. Blending the power of AI with the precision of genomic expertise, the company empowers pharmaceutical companies and the clinical diagnostic community with empirical genomic evidence and insights that both support the development of novel therapeutics and speed diagnostic assessments and treatment recommendations.

Read the Article
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.